

20427 U.S. PTO
030304UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	RS0208
First Inventor or Application Identifier	Jason M. Johnson
Title	ALTERNATIVELY SPLICED ISOFORMS OF INHIBITOR OF KAPPA-B KINASE GAMMA (IKBKG)
Express Mail Label No.	ER 754456486 US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Commissioner for Patents Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
2. <input checked="" type="checkbox"/> Specification [Total Pages 46]	a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 1]	b. <input checked="" type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper
4. Oath or Declaration a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).	c. <input checked="" type="checkbox"/> Statements verifying identity of above copies
5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	ACCOMPANYING APPLICATION PARTS 7. <input type="checkbox"/> Assignment papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney 9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 10. <input type="checkbox"/> Preliminary Amendment 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 12. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 13. <input type="checkbox"/> Other: _____

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. ____ / ____
Prior application information: Examiner _____ Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

☒ Correspondence address below

NAME	R. Douglas Bradley				
ADDRESS	Merck & Co., Inc., P.O. Box 2000 - Patent Department RY60-30				
CITY	Rahway	STATE	New Jersey	ZIP CODE	07065-0907
COUNTRY	USA	TELEPHONE	732-594-5321	FAX	732-594-4720

Name	R. Douglas Bradley	Registration No. (Attorney/Agent)	44,553
Signature	R Douglas Bradley	Date	3/3/2004


EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT March 3, 2004

EXPRESS MAIL NO. ER 754456486 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY



DATE March 3, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

Deposit Acct. 502287
Rosetta Inpharmatics LLC
Our Case Docket No. RS0208

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):
Jason M. Johnson, Philip W. Garrett-Engle, and Zhengyan Kan

For: ALTERNATIVELY SPLICED ISOFORMS OF INHIBITOR OF KAPPA-B KINASE GAMMA (IKBKG)

For	Number Filed	Number Extra	Rate	Basic Fee \$750
Total Claims	24 - 20 =	4 X	\$18	= \$72
Independent Claims	6 - 3 =	3 X	\$84	= \$252
Multiple Dependent Claims*			\$280	= \$0
*Add this fee if application contains any multiple dependent claims, regardless of number.		TOTAL FILING FEE		\$1074

The Assistant Commissioner is hereby authorized to charge \$1074 and any additional fees which may be required to Account No. 502287. Duplicate copy of this sheet is enclosed.

☐ Under provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT March 3, 2004

EXPRESS MAIL NO. ER 754456486 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY Cheryl Bra

DATE March 3, 2004

Respectfully,

R. Douglas Bradley

By: R. Douglas Bradley
Attorney for Applicant(s)
Reg. No. 44,553
Rosetta Inpharmatics LLC
401 Terry Avenue North
Seattle, Washington 98109
(206)802-6301

Date: March 3, 2004